ATE454140T1 - Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität - Google Patents

Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität

Info

Publication number
ATE454140T1
ATE454140T1 AT05732660T AT05732660T ATE454140T1 AT E454140 T1 ATE454140 T1 AT E454140T1 AT 05732660 T AT05732660 T AT 05732660T AT 05732660 T AT05732660 T AT 05732660T AT E454140 T1 ATE454140 T1 AT E454140T1
Authority
AT
Austria
Prior art keywords
optically pure
dopamine agonist
preferred
sedative agent
desmethylzopiclone
Prior art date
Application number
AT05732660T
Other languages
English (en)
Inventor
Timothy Barberich
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE454140T1 publication Critical patent/ATE454140T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05732660T 2004-02-18 2005-02-07 Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität ATE454140T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54541304P 2004-02-18 2004-02-18
PCT/US2005/003937 WO2005079851A2 (en) 2004-02-18 2005-02-07 Dopamine-agonist combination therapy with sedatives for improving sleep quality

Publications (1)

Publication Number Publication Date
ATE454140T1 true ATE454140T1 (de) 2010-01-15

Family

ID=34886149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732660T ATE454140T1 (de) 2004-02-18 2005-02-07 Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität

Country Status (10)

Country Link
US (2) US20050267176A1 (de)
EP (1) EP1742624B1 (de)
JP (1) JP2007523165A (de)
AT (1) ATE454140T1 (de)
AU (2) AU2005215376B2 (de)
CA (1) CA2556870C (de)
DE (1) DE602005018763D1 (de)
DK (1) DK1742624T3 (de)
ES (1) ES2337700T3 (de)
WO (1) WO2005079851A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
DE602005018763D1 (de) 2004-02-18 2010-02-25 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
WO2005097132A2 (en) 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
JP5156381B2 (ja) * 2004-10-18 2013-03-06 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｎ−メチル−Ｎ−（３−｛３−［２−チエニルカルボニル］−ピラゾール−［１，５−α］−ピリミジン−７−イル｝フェニル）アセトアミドの水和物ならびにそれに関連するプロセスおよび方法
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
CA2957667A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US20070270590A1 (en) * 2006-04-20 2007-11-22 Marioara Mendelovici Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
US20080045547A1 (en) * 2006-07-07 2008-02-21 Lippa Arnold S Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
EP1987815A1 (de) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen
US20080299189A1 (en) * 2007-06-04 2008-12-04 Drugtech Corporation Controlled release dopamine agonist compositions
EP2020403A1 (de) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Verfahren zur Auflösung von Zopiclon und Zwischenprodukten
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2742841A1 (en) * 2008-11-06 2010-05-14 Biotie Therapies, Inc. Treatment of restless leg syndrome and sleep disorders
CA3037010A1 (en) * 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
CN104316631A (zh) 2009-01-30 2015-01-28 桑诺维恩药品公司 一种检测包衣的固体口服剂型中外露核芯物质的存在的方法
EP3132793A1 (de) * 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadinzusammensetzungen und verfahren zur verwendung
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2994952A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
CN109563018A (zh) 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸钠的共晶及其用途
KR102338171B1 (ko) 2016-06-13 2021-12-09 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
US11612607B2 (en) 2016-08-31 2023-03-28 Taro Pharmaceuticals Industries Ltd. Fenoldopam topical formulations for treating skin disorders
BR112020003375A2 (pt) 2017-08-24 2020-08-25 Adamas Pharma, Llc composições de amantadina, preparações das mesmas, e métodos de uso
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
BR112021017140A2 (pt) 2019-03-08 2021-11-09 Taro Pharma Ind Composições tópicas estáveis de fenoldopam
SG11202112822VA (en) * 2019-04-22 2021-12-30 Robert Knobler Non-hormonal treatment of hot flashes

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US4505029A (en) * 1981-03-23 1985-03-19 General Electric Company Semiconductor device with built-up low resistance contact
US4419345A (en) * 1981-07-20 1983-12-06 Kinetic Systems, Inc. Sleep-inducing pharmaceutical composition and method
DE3228351C2 (de) * 1982-07-29 1985-07-25 Merckle GmbH, 7902 Blaubeuren Arzneimittel zur Behandlung von Schlafstörungen
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4654347A (en) 1983-06-23 1987-03-31 American Cyanamid Company Aryl and heteroaryl[[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
FR2606410B1 (fr) 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
US5017616A (en) * 1989-11-30 1991-05-21 Jeffrey Askanazi Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US5538977A (en) 1995-03-17 1996-07-23 American Cyanamid Company 3-Substituted-7-[3-(imidazol-1-yl)phenyl]-pyrazolo[1,5-a]pyrimidines
IT1276522B1 (it) 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US5714607A (en) 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
CZ296464B6 (cs) * 1997-03-12 2006-03-15 Addex Pharmaceuticals Sa Farmaceutický prostredek pro lécení nebo prevenciporuch spánku a/nebo potízí se spánkem
WO1999063977A2 (en) * 1998-06-09 1999-12-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
EP1005863A1 (de) 1998-12-04 2000-06-07 Synthelabo Dosisformen mit gesteuerter Wirkstofffreigabe enthaltend ein kurzer wirkung Hypnotikum oder einem Salz davon
SI1169029T1 (sl) * 1999-03-19 2005-12-31 Abbott Gmbh & Co Kg Uporaba sibutramina ali njegova derivata za zdravljenje motenj med spanjem
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
US6231594B1 (en) * 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
AU2003285012A1 (en) * 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
PL1641456T3 (pl) 2003-06-25 2010-08-31 H Lundbeck As Gaboksadol do leczenia depresji i innych zaburzeń afektywnych
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
WO2005063297A2 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
WO2005072715A1 (en) * 2004-01-29 2005-08-11 Sepracor Inc. Use of (s)-didesmethylsibutraminefor treating, preventing and managing a sleep disorder
DE602005018763D1 (de) 2004-02-18 2010-02-25 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
US7465729B2 (en) 2004-04-05 2008-12-16 Sepracor Inc. Methods of treatment of menopause and perimenopause using eszopiclone
WO2005097132A2 (en) 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
JP2009500420A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
CA2957667A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007005940A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
CN101257907A (zh) 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合

Also Published As

Publication number Publication date
CA2556870C (en) 2014-01-28
DK1742624T3 (da) 2010-03-08
AU2005215376B2 (en) 2011-01-20
ES2337700T3 (es) 2010-04-28
EP1742624B1 (de) 2010-01-06
WO2005079851A2 (en) 2005-09-01
AU2005215376A1 (en) 2005-09-01
US8877755B2 (en) 2014-11-04
DE602005018763D1 (de) 2010-02-25
EP1742624A2 (de) 2007-01-17
AU2011201703A1 (en) 2011-05-12
WO2005079851A3 (en) 2006-06-22
JP2007523165A (ja) 2007-08-16
US20050267176A1 (en) 2005-12-01
US20100004251A1 (en) 2010-01-07
CA2556870A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE454140T1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
ME02495B (de) Behandlung bdnf-assoziierter erkrankungen mit laquinimod
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2020009911A (es) Usos de inhibiores de dpp iv.
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
MX2009013989A (es) Terapia en combinacion para depresion.
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
CL2008003363A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual.
EA200970435A1 (ru) Лечение общих расстройств развития
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE410163T1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
ATE516366T1 (de) Regulierte aptamer-therapeutika
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties